カテゴリ： MarketsandMarkets, 世界, 医療/バイオ

デジタルセラピューティクス（DTx）の世界市場予測（～2028）：提供別、収益モデル別、用途別

■ 英語タイトル：Digital Therapeutics (DTx) Market by Offerings (Platform, Virtual Reality/Games), Revenue Model (Subscription, Value Based), Application (Therapy (Diabetes, Obesity, CNS, Respiratory, CVD), Drug Adherence, Rehab/Patient care) - Global Forecast to 2028

調査会社MarketsandMarkets社が発行したリサーチレポート（データ管理コード：HIT4407-24）■ 発行会社/調査会社：MarketsandMarkets
■ 商品コード：HIT4407-24
■ 発行日：2024年1月23日
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：297
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,950 ⇒換算￥742,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥997,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥1,222,500見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[デジタルセラピューティクス（DTx）の世界市場予測（～2028）：提供別、収益モデル別、用途別]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

“デジタルセラピューティクス（DTx）市場は、予測期間中の年平均成長率29.1％で、2023年の61億米ドルから2028年には219億米ドルに達すると予測”デジタルセラピューティクス（DTx）の急速な普及は、慢性疾患と闘う患者数の増加や、この分野への投資の拡大といった要因によるものです。しかしながら、市場成長の阻害要因としては、発展途上国におけるデジタル治療プログラムに対する認識やアクセスの不足、従来の医療提供者の抵抗、不均等な支払いモデルの存在などが挙げられます。

“サブスクリプションベースの収益モデルセグメントは、予測期間中、市場で最大かつ最も急成長しているカテゴリ”
デジタルセラピューティクス（DTx）市場の収益モデルセグメントは、サブスクリプション、一括購入/ライセンス、成果/価値ベースに分類されます。2022年には、サブスクリプションセグメントが最大の市場シェアを占めました。デジタルセラピューティクス（DTx）は長期的な健康成果を目指すことが多く、ユーザーは長期にわたってプログラムにコミットする必要があります。サブスクリプションモデルは、インセンティブやプラットフォームの機能への継続的なアクセスを提供することで、ユーザーのコミットメントを促します。

“糖尿病分野は予測期間中に最も高い成長率が見込まれる”
治療/ケア関連アプリケーションの種類に関して、デジタルセラピューティクス（DTx）市場は糖尿病、中枢神経系疾患、慢性呼吸器疾患、筋骨格系疾患、心血管疾患、禁煙、服薬アドヒアランス、消化器疾患、薬物使用障害・中毒管理、リハビリテーション・患者ケア、その他の治療/ケア関連アプリケーションに分類されます。
治療／ケア関連アプリケーションの中では、糖尿病分野が予測期間中に最も高い成長率を記録する見通しです。糖尿病におけるデジタル治療市場は、2022年に最大のシェアを占めました。推進要因としては、糖尿病の有病率の増加、糖尿病に関連する多額の医療費、費用対効果の高いソリューションによる負担軽減に焦点を当てた政府のイニシアチブの高まりなどが挙げられます。

“予測期間中、B2Bセグメントが最も高いCAGRで成長する見込み”
販売チャネルに関して、デジタルセラピューティクス（DTx）市場は企業対顧客（B2C）と企業対企業（B2B）に区分されます。B2B分野は予測期間中に最も高いCAGRを示すと予測され、その理由は、デジタルセラピューティクス（DTx）を医薬品と統合するために製薬会社とデジタルヘルス企業とのパートナーシップが拡大しているためです。製薬企業は、デジタルセラピューティクス（DTx）プロバイダーとの戦略的提携や買収に積極的に取り組んでいます。これらの提携により、製薬会社はデジタルセラピューティクス（DTx）をより広範なヘルスケアソリューションに統合し、患者ケアへの総合的なアプローチを提供することができます。さらに、保険会社や医療提供者を含む支払者は、価値ベースのケアモデルをますます受け入れています。デジタル・セラピューティクスは、アウトカム、予防、費用対効果を重視することで、こうしたモデルに合致しています。支払者は、予防的介入を通じて医療費を削減するDTxの可能性を見ており、最終的に採用を促進しています。

“北米が最大かつ最も急成長する地域市場に”
アメリカとカナダで構成される北米は、2022年のデジタルセラピューティクス（DTx）市場で大きなシェアを占めています。技術進歩に資金を提供する政府の制度や、デジタルセラピューティクス（DTx）に対する有利な償還構造などの要因が、この地域の市場成長を促進すると予測されています。また、北米の支払者や医療提供者は、デジタルセラピューティクス（DTx）の早期導入者です。同地域では、保険会社、医療提供者、その他の利害関係者がDTxの臨床効果と費用対効果を認識し、積極的に取り組んでいます。このような早期の賛同が、さまざまな医療環境での広範な採用を後押ししています。

本レポートのために実施した主なインタビューは以下のように分類されます：

- 企業タイプ別 ティア1（50％）、ティア2（30％）、ティア3（20％）
- 役職別 Cレベル (75％)、Dレベル (15％)、その他 (10％)
- 地域別 北米（70％）、ヨーロッパ（20％）、アジア太平洋（7％）、その他地域（3％）

デジタルセラピューティクス（DTx）市場の主要企業

同市場の主要プレーヤーは、Noom, Inc (US), Teladoc Health, Inc. (US), Omada Health, Inc. (US), WellDoc, Inc (US), Biofourmis (US), Better Therapeutics, Inc. (US), Amalgm Rx (US), CogniFit Inc (US), Headspace Health (US), Propeller Health (US), Virta Health Corp (US), 2Morrow, Inc. (US), Realizedcare (US), Canary Health (US), Twill Inc. (US), Click Therapeutics, Inc. (US), Akili, Inc. (US), Cognoa, Inc (US), Wellthy Therapeutics Pvt. Ltd. (India), Kaia Health (Germany), Ayogo (Canada), Mindable Health GmbH (Germany), Hinge Health, Inc. (US), Freespira (US)です。

調査範囲

この調査レポートは、デジタルセラピューティクス（DTx）市場の質的および量的分析を掲載しています。本レポートの主な目的は、販売チャネル、収益モデル、用途、サービス、地域など、さまざまなセグメントにわたる市場規模と今後の成長可能性を推定することです。また、本レポートは、著名な市場プレイヤーの財務情報、最近の動向、企業プロフィール、最近の開発、および一般的な市場戦略とともに、広範な競合分析で構成されています。

レポート購入の主な利点

本レポートは、デジタルセラピューティクス（DTx）市場全体とそのサブセグメント両方の収益数値の近似値を提供することで、市場リーダーと新規参入者を支援することを目的としています。関係者は本レポートを活用することで、競争環境を把握し、戦略的な事業ポジショニングのための洞察力を獲得し、効果的な市場参入戦略を策定することができます。さらに、市場ダイナミクスを評価する手段を関係者に提供し、重要な市場機会、阻害要因、促進要因、および課題に関する情報を提供します。

レポート購入の理由
本レポートは、既存企業だけでなく、新規参入企業や中小企業も市場の動向を把握するのに役立ちます。本レポートを購入された企業は、以下の戦略の1つまたは組み合わせを使用して、市場での地位を強化することができます。

本レポートは以下の洞察を提供します：

- デジタルセラピューティクス（DTx）市場の成長に影響を与える主な促進要因（予防可能な慢性疾患の罹患率の増加、予防医療への注目の高まり、医療費抑制の必要性、ベンチャーキャピタル投資の大幅な増加）、機会（新興市場における成長見通し、未診断・未治療の患者人口の多さ、予期せぬ治療用途）の分析しました。
- 製品開発/イノベーション： デジタルセラピューティクス（DTx）市場における今後の技術、研究開発活動、新製品発売に関する詳細な洞察を提供します。
- 市場開発： 当レポートでは、さまざまな地域や国のデジタルセラピューティクス（DTx）市場を分析しています。
- 市場の多様化： デジタルセラピューティクス（DTx）市場における新しいソフトウェアやプログラム、未開拓の地域、最近の開発、投資に関する情報を網羅。
- 競合評価： 本レポートは、市場における主要企業および主要中小企業/新興企業に関する詳細な洞察を提供します。成長戦略、市場シェア、各プレイヤーの製品・サービス内容、市場の主要動向などを詳細に評価しています。本レポートにより、関係者はデジタルセラピューティクス（DTx）市場の動向を把握し、促進要因、課題、阻害要因、機会などの情報を得ることができます。

1.　序論
2.　調査方法
3.　エグゼクティブサマリー
4.　プレミアムインサイト
5.　市場概要
6．世界のデジタルセラピューティクス（DTx）市場規模：提供別
7.　世界のデジタルセラピューティクス（DTx）市場規模：用途別
8.　世界のデジタルセラピューティクス（DTx）市場規模：収益モデル別
9.　世界のデジタルセラピューティクス（DTx）市場規模：販売チャネル別
10.　世界のデジタルセラピューティクス（DTx）市場規模：地域別
11.　競争状況
12.　企業情報
13.　付録

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 INTRODUCTION 40
1.1 STUDY OBJECTIVES 40
1.2 MARKET DEFINITION 40
1.3 INCLUSIONS AND EXCLUSIONS 40
1.4 MARKET SCOPE 41
1.4.1 MARKETS COVERED 41
1.4.2 YEARS CONSIDERED 42
1.4.3 CURRENCY CONSIDERED 42
1.5 STAKEHOLDERS 42
1.6 RESEARCH LIMITATIONS 43
1.7 SUMMARY OF CHANGES 43
1.8 RECESSION IMPACT 44
2 RESEARCH METHODOLOGY 45
2.1 RESEARCH DATA 45
FIGURE 1 RESEARCH DESIGN 45
2.1.1 SECONDARY DATA 46
2.1.1.1 Key data from secondary sources 47
2.1.2 PRIMARY DATA 47
FIGURE 2 PRIMARY SOURCES 47
2.1.2.1 Key data from primary sources 48
2.1.2.2 Key industry insights 49
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 50
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY TYPE OF BUYER AND REGION 50
2.2 MARKET SIZE ESTIMATION 51
2.2.1 BOTTOM-UP APPROACH 51
2.2.1.1 Approach 1: Revenue mapping-based estimation 51
FIGURE 5 DIGITAL THERAPEUTICS: REVENUE MAPPING-BASED ESTIMATION 52
2.2.1.2 Approach 2: Buyer adoption-based estimation 52
FIGURE 6 DIGITAL THERAPEUTICS ESTIMATION: BUYER ADOPTION-BASED ESTIMATION 52
2.2.2 TOP-DOWN APPROACH: PENETRATION RATE-BASED MARKET SIZE ESTIMATION 53
FIGURE 7 PENETRATION RATE-BASED MARKET ESTIMATION 53
2.2.3 GROWTH FORECAST 53
TABLE 1 IMPACT ANALYSIS 54
FIGURE 8 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2023–2028) 55
FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 56
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 56
FIGURE 10 DATA TRIANGULATION METHODOLOGY 57
2.4 ASSUMPTIONS 57
2.5 RISK ASSESSMENT 58
3 EXECUTIVE SUMMARY 59
FIGURE 11 DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2023 VS. 2028 (USD MILLION) 59
FIGURE 12 DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2023 VS. 2028 (USD MILLION) 60
FIGURE 13 DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 60
FIGURE 14 DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2023 VS. 2028 (USD MILLION) 61
FIGURE 15 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2023 VS. 2028 (USD MILLION) 62
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF DIGITAL THERAPEUTICS MARKET 63
4 PREMIUM INSIGHTS 64
4.1 DIGITAL THERAPEUTICS MARKET OVERVIEW 64
FIGURE 17 INCREASING INCIDENCE OF CHRONIC DISEASES AND RISING NEED TO CURB HEALTHCARE COSTS TO DRIVE MARKET 64
4.2 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2023 VS. 2O28 65
FIGURE 18 B2B SALES CHANNEL SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 65
4.3 DIGITAL THERAPEUTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 66
FIGURE 19 US TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 66
5 MARKET OVERVIEW 67
5.1 INTRODUCTION 67
5.2 MARKET DYNAMICS 67
FIGURE 20 DIGITAL THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 67
5.2.1 DRIVERS 68
5.2.1.1 Increasing incidence of chronic diseases 68
5.2.1.2 Growing focus on preventive healthcare 69
5.2.1.3 Rising need to curb healthcare cost 69
5.2.1.4 Surge in venture capital investments 70
5.2.1.5 Benefits of digital therapeutics 71
5.2.1.5.1 Ability to induce behavioral change 71
5.2.1.5.2 Improved drug adherence 71
5.2.1.5.3 Patient convenience and user-friendly 72
5.2.2 RESTRAINTS 72
5.2.2.1 Data privacy concerns 72
5.2.3 OPPORTUNITIES 72
5.2.3.1 High growth potential of emerging markets 72
5.2.3.2 Large undiagnosed and untreated population 73
5.2.4 CHALLENGES 73
5.2.4.1 Unstable pricing models 73
5.2.4.2 Reluctance among patients for DTx adoption 74
5.2.4.3 Limited awareness in emerging economies 74
5.2.4.4 Resistance from traditional healthcare providers 74
5.3 INDUSTRY TRENDS 75
5.3.1 VIRTUAL REALITY 75
5.3.2 RISING DEMAND FOR DIGITAL SOLUTIONS IN CBT 75
5.4 TECHNOLOGY ANALYSIS 76
TABLE 2 TECHNOLOGY ENABLERS, BENEFITS, AND EXAMPLES 76
5.4.1 MACHINE LEARNING 76
5.4.2 ARTIFICIAL INTELLIGENCE 77
5.4.3 INTERNET OF THINGS 77
5.4.4 BLOCKCHAIN TECHNOLOGY 77
5.4.5 CLOUD COMPUTING 78
5.4.6 DATA ANALYTICS 78
5.4.7 EXTENDED REALITY 78
5.5 VALUE CHAIN ANALYSIS 79
FIGURE 21 DIGITAL THERAPEUTICS MARKET: VALUE CHAIN ANALYSIS 79
5.5.1 RESEARCH & PRODUCT DEVELOPMENT 79
5.5.2 MATERIAL COMPONENTS 79
5.5.3 MANUFACTURERS & DEVELOPERS 80
5.5.4 DISTRIBUTION & SALES 80
5.5.5 END-USER INDUSTRIES 80
5.5.6 POST-SALE SERVICES 80
5.6 ECOSYSTEM ANALYSIS 81
FIGURE 22 ECOSYSTEM MARKET/MAP 81
5.7 PIPELINE PRODUCTS 84
5.8 CASE STUDY ANALYSIS 84
5.8.1 CASE STUDY 1: WELLTHY THERAPEUTICS (INDIA) 84
5.8.2 CASE STUDY 2: HAPPIFY HEALTH (US) 85
5.8.3 CASE STUDY 3: OMADA HEALTH (US) 85
5.9 PORTER’S FIVE FORCES ANALYSIS 85
5.9.1 THREAT OF NEW ENTRANTS 86
5.9.2 BARGAINING POWER OF SUPPLIERS 86
5.9.3 BARGAINING POWER OF BUYERS 86
5.9.4 THREAT OF SUBSTITUTES 87
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 87
5.10 REGULATORY LANDSCAPE 87
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 3 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 4 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
TABLE 5 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 6 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
TABLE 7 DIGITAL THERAPEUTICS MARKET: REGULATORY DATA NEEDED FOR CLASS II DEVICES 95
5.11 PRICING ANALYSIS 96
5.11.1 COSTS INVOLVED IN DIGITAL THERAPEUTICS 96
5.11.2 INDICATIVE PRICING ANALYSIS, BY KEY PLAYER & COUNTRY 96
TABLE 8 AVERAGE SELLING PRICE OF DIGITAL THERAPEUTIC PRODUCTS, BY COUNTRY 96
5.11.3 INDICATIVE PRICING ANALYSIS OF DIGITAL THERAPEUTICS, BY REGION 97
FIGURE 23 INDICATIVE PRICING ANALYSIS OF TELEHEALTH & TELEMEDICINE DEVICES, BY REGION 97
5.12 REIMBURSEMENT SCENARIO 98
TABLE 9 DIGITAL THERAPEUTICS MARKET: GLOBAL COVERAGE DETERMINATION STANDARDS 99
5.13 PATENT ANALYSIS 100
5.13.1 PATENT PUBLICATION TRENDS 100
FIGURE 24 LIST OF MAJOR PATIENTS FOR DIGITAL THERAPEUTICS 100
5.13.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 100
FIGURE 25 TOP APPLICANT COUNTRIES FOR DIGITAL THERAPEUTICS PATENTS (JANUARY 2016–NOVEMBER 2023) 101
5.13.3 LIST OF MAJOR PATENTS 101
TABLE 10 KEY PATENTS IN DIGITAL THERAPEUTICS MARKET 101
5.14 KEY CONFERENCES AND EVENTS 102
TABLE 11 DIGITAL THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023−2024) 102
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 103
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 103
FIGURE 26 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR SALES CHANNEL 103
TABLE 12 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR SALES CHANNEL, BY RANKING 103
5.15.2 BUYING CRITERIA 104
FIGURE 27 KEY BUYING CRITERIA FOR SALES CHANNEL 104
TABLE 13 KEY BUYING CRITERIA FOR SALES CHANNEL, BY RANKING 104
5.16 REVENUE SHIFT AND NEW REVENUE POCKETS FOR DIGITAL THERAPEUTICS MARKET 104
FIGURE 28 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 105
5.17 INVESTMENT LANDSCAPE 105
FIGURE 29 INVESTOR DEALS & FUNDING INITIATIVES FOR DIGITAL THERAPEUTICS (2022) 105
FIGURE 30 TOP FUNDING CATEGORIES FOR DIGITAL HEALTH IN 2021 106
FIGURE 31 MOST VALUED TELEHEALTH & TELEMEDICINE FIRMS IN 2022 (USD BILLION) 106
6 DIGITAL THERAPEUTICS MARKET, BY OFFERING 107
6.1 INTRODUCTION 108
TABLE 14 DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 108
6.2 SOFTWARE/PLATFORMS 108
6.2.1 ABILITY TO PROVIDE SCALABLE SOLUTIONS FOR DEPLOYMENT TO PROPEL MARKET 108
TABLE 15 DIGITAL THERAPEUTICS MARKET FOR SOFTWARE/PLATFORMS, BY REGION, 2021–2028 (USD MILLION) 109
6.3 PROGRAMS 109
6.3.1 INTRODUCTION OF EVIDENCE-BASED THERAPEUTIC PROGRAMS TO SUPPORT MARKET GROWTH 109
TABLE 16 DIGITAL THERAPEUTICS MARKET FOR PROGRAMS, BY REGION, 2021–2028 (USD MILLION) 110
6.4 VIRTUAL REALITY/GAMES 110
6.4.1 RISING DEMAND FOR VR SOLUTIONS TO DRIVE MARKET 110
TABLE 17 DIGITAL THERAPEUTICS MARKET FOR VIRTUAL REALITY/GAMES, BY REGION, 2021–2028 (USD MILLION) 111
7 DIGITAL THERAPEUTICS MARKET, BY APPLICATION 112
7.1 INTRODUCTION 113
TABLE 18 DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 113
7.2 TREATMENT/CARE-RELATED APPLICATIONS 113
TABLE 19 DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 114
TABLE 20 DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 114
7.2.1 DIABETES 115
7.2.1.1 Rising prevalence of diabetes to drive market 115
TABLE 21 DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY REGION, 2021–2028 (USD MILLION) 115
7.2.2 CENTRAL NERVOUS SYSTEM (CNS) DISORDERS 115
TABLE 22 DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 116
TABLE 23 DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY REGION, 2021–2028 (USD MILLION) 116
7.2.2.1 Mental health disorders 116
7.2.2.1.1 Benefits of digital therapeutics in managing mental health disorders to drive R&D 116
TABLE 24 DIGITAL THERAPEUTICS MARKET FOR MENTAL HEALTH DISORDERS, BY REGION, 2021–2028 (USD MILLION) 117
7.2.2.2 Other CNS disorders 117
TABLE 25 DIGITAL THERAPEUTICS MARKET FOR OTHER CNS DISORDERS, BY REGION, 2021–2028 (USD MILLION) 117
7.2.3 SMOKING CESSATION 118
7.2.3.1 Rising development of mobile applications for nicotine addiction treatment to drive market 118
TABLE 26 DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY REGION, 2021–2028 (USD MILLION) 118
7.2.4 CHRONIC RESPIRATORY DISEASES 118
7.2.4.1 Growing prevalence of COPD and asthma to drive market 118
TABLE 27 DIGITAL THERAPEUTICS MARKET FOR CHRONIC RESPIRATORY DISEASES, BY REGION, 2021–2028 (USD MILLION) 119
7.2.5 MUSCULOSKELETAL DISORDERS 119
7.2.5.1 Shortage of physiotherapists to boost demand 119
TABLE 28 DIGITAL THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 119
7.2.6 CARDIOVASCULAR DISEASES 120
7.2.6.1 High incidence of CVD to propel market 120
TABLE 29 DIGITAL THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION) 120
7.2.7 MEDICATION ADHERENCE 120
7.2.7.1 Rising number of non-adherence cases to propel market 120
TABLE 30 DIGITAL THERAPEUTICS MARKET FOR MEDICATION ADHERENCE, BY REGION, 2021–2028 (USD MILLION) 121
7.2.8 GASTROINTESTINAL DISORDERS 121
7.2.8.1 Rising incidence of IBS and GERD to support market growth 121
TABLE 31 DIGITAL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 121
7.2.9 REHABILITATION & PATIENT CARE 122
7.2.9.1 Increasing focus on development of patient care platforms to drive market 122
TABLE 32 DIGITAL THERAPEUTICS MARKET FOR REHABILITATION & PATIENT CARE, BY REGION, 2021–2028 (USD MILLION) 122
7.2.10 SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT 122
7.2.10.1 Growing focus on behavioral interventions to propel market 122
TABLE 33 DIGITAL THERAPEUTICS MARKET FOR SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT, BY REGION, 2021–2028 (USD MILLION) 123
7.2.11 OTHER TREATMENT/CARE-RELATED APPLICATIONS 123
TABLE 34 DIGITAL THERAPEUTICS MARKET FOR OTHER TREATMENT/CARE-RELATED APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 123
7.3 PREVENTIVE APPLICATIONS 124
TABLE 35 DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 124
TABLE 36 DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 125
7.3.1 PREDIABETES 125
7.3.1.1 Focus on reducing type 2 diabetes to support market growth 125
TABLE 37 DIGITAL THERAPEUTICS MARKET FOR PREDIABETES, BY REGION, 2021–2028 (USD MILLION) 125
7.3.2 OBESITY 126
7.3.2.1 Availability of cost-effective solutions for obesity management to propel market 126
TABLE 38 DIGITAL THERAPEUTICS MARKET FOR OBESITY, BY REGION, 2021–2028 (USD MILLION) 126
7.3.3 NUTRITION 126
7.3.3.1 Sedentary lifestyles and unhealthy diets to boost demand 126
TABLE 39 DIGITAL THERAPEUTICS MARKET FOR NUTRITION, BY REGION, 2021–2028 (USD MILLION) 127
7.3.4 LIFESTYLE MANAGEMENT 127
7.3.4.1 Aim to promote holistic lifestyles to drive market 127
TABLE 40 DIGITAL THERAPEUTICS MARKET FOR LIFESTYLE MANAGEMENT, BY REGION, 2021–2028 (USD MILLION) 127
7.3.5 OTHER PREVENTIVE APPLICATIONS 128
TABLE 41 DIGITAL THERAPEUTICS MARKET FOR OTHER PREVENTIVE APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 128
8 DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL 129
8.1 INTRODUCTION 130
TABLE 42 DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 130
8.2 SUBSCRIPTION-BASED MODEL 130
8.2.1 FLEXIBILITY IN PAYMENT OPTIONS TO DRIVE MARKET 130
TABLE 43 DIGITAL THERAPEUTICS MARKET FOR SUBSCRIPTION-BASED MODEL, BY REGION, 2021–2028 (USD MILLION) 131
8.3 ONE-TIME PURCHASE/ANNUAL LICENSING MODEL 131
8.3.1 BENEFITS OF LIMITED RECURRING PAYMENTS TO BOOST DEMAND 131
TABLE 44 DIGITAL THERAPEUTICS MARKET FOR ONE-TIME PURCHASE/ANNUAL LICENSING MODEL, BY REGION, 2021–2028 (USD MILLION) 132
8.4 OUTCOME /VALUE-BASED MODEL 132
8.4.1 RESULT-DRIVEN APPROACH THAT ENHANCES END-USER ENGAGEMENT TO PROPEL MARKET 132
TABLE 45 DIGITAL THERAPEUTICS MARKET FOR OUTCOME/VALUE-BASED MODEL, BY REGION, 2021–2028 (USD MILLION) 133
9 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL 134
9.1 INTRODUCTION 135
TABLE 46 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 135
9.2 B2B SALES CHANNEL 135
TABLE 47 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 135
TABLE 48 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY REGION, 2021–2028 (USD MILLION) 136
9.2.1 PAYERS 136
9.2.1.1 Significant cost savings to boost demand 136
TABLE 49 DIGITAL THERAPEUTICS MARKET FOR PAYERS, BY REGION, 2021–2028 (USD MILLION) 137
9.2.2 EMPLOYERS 137
9.2.2.1 Rising importance of employee health management to drive market 137
TABLE 50 DIGITAL THERAPEUTICS MARKET FOR EMPLOYERS, BY REGION, 2021–2028 (USD MILLION) 138
9.2.3 PHARMACEUTICAL COMPANIES 138
9.2.3.1 Cross-industry collaborations between start-ups and pharma companies to propel market 138
TABLE 51 DIGITAL THERAPEUTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION) 139
9.2.4 PROVIDERS 139
9.2.4.1 Advanced patient management and cost-reduction benefits to support market growth 139
TABLE 52 DIGITAL THERAPEUTICS MARKET FOR PROVIDERS, BY REGION, 2021–2028 (USD MILLION) 140
9.2.5 OTHER BUYERS 140
TABLE 53 DIGITAL THERAPEUTICS MARKET FOR OTHER BUYERS, BY REGION, 2021–2028 (USD MILLION) 140
9.3 B2C SALES CHANNEL 141
TABLE 54 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 141
TABLE 55 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY REGION, 2021–2028 (USD MILLION) 141
9.3.1 CAREGIVERS 142
9.3.1.1 Ability to manage chronic conditions effectively to boost demand 142
TABLE 56 DIGITAL THERAPEUTICS MARKET FOR CAREGIVERS, BY REGION, 2021–2028 (USD MILLION) 142
9.3.2 PATIENTS 142
9.3.2.1 Growing awareness of preventive health to support market 142
TABLE 57 DIGITAL THERAPEUTICS MARKET FOR PATIENTS, BY REGION, 2021–2028 (USD MILLION) 143
10 DIGITAL THERAPEUTICS MARKET, BY REGION 144
10.1 INTRODUCTION 145
TABLE 58 DIGITAL THERAPEUTICS MARKET, BY REGION, 2021–2028 (USD MILLION) 145
10.2 NORTH AMERICA 145
FIGURE 32 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET SNAPSHOT 146
TABLE 59 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 60 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 147
TABLE 61 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 147
TABLE 62 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 148
TABLE 63 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 64 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 149
TABLE 65 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 149
TABLE 66 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 149
TABLE 67 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 150
TABLE 68 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 150
10.2.1 NORTH AMERICA: RECESSION IMPACT 150
10.2.2 US 151
10.2.2.1 Rising technological advancements to boost demand 151
TABLE 69 US: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 152
TABLE 70 US: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 152
TABLE 71 US: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 152
TABLE 72 US: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 73 US: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 74 US: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 75 US: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 154
TABLE 76 US: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 154
TABLE 77 US: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 155
10.2.3 CANADA 155
10.2.3.1 Favorable government initiatives for advanced healthcare solutions to support market growth 155
TABLE 78 CANADA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 156
TABLE 79 CANADA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 156
TABLE 80 CANADA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 157
TABLE 81 CANADA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 82 CANADA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 158
TABLE 83 CANADA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 158
TABLE 84 CANADA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 158
TABLE 85 CANADA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 159
TABLE 86 CANADA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 159
10.3 EUROPE 159
TABLE 87 EUROPE: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 160
TABLE 88 EUROPE: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 160
TABLE 89 EUROPE: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 161
TABLE 90 EUROPE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 161
TABLE 91 EUROPE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 162
TABLE 92 EUROPE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 162
TABLE 93 EUROPE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 163
TABLE 94 EUROPE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 163
TABLE 95 EUROPE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 163
TABLE 96 EUROPE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 164
10.3.1 EUROPE: RECESSION IMPACT 164
10.3.2 GERMANY 164
10.3.2.1 Rising investments in digital health applications to drive market 164
TABLE 97 GERMANY: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 165
TABLE 98 GERMANY: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 165
TABLE 99 GERMANY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 165
TABLE 100 GERMANY: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 101 GERMANY: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 102 GERMANY: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 167
TABLE 103 GERMANY: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 167
TABLE 104 GERMANY: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 167
TABLE 105 GERMANY: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 168
10.3.3 UK 168
10.3.3.1 High adoption of HCIT solutions to propel market 168
TABLE 106 UK: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 169
TABLE 107 UK: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 169
TABLE 108 UK: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 169
TABLE 109 UK: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 170
TABLE 110 UK: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 170
TABLE 111 UK: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 171
TABLE 112 UK: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 171
TABLE 113 UK: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 171
TABLE 114 UK: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 172
10.3.4 FRANCE 172
10.3.4.1 Favorable health insurance system to boost demand 172
TABLE 115 FRANCE: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 172
TABLE 116 FRANCE: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 173
TABLE 117 FRANCE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 173
TABLE 118 FRANCE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 174
TABLE 119 FRANCE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 174
TABLE 120 FRANCE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 121 FRANCE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 175
TABLE 122 FRANCE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 175
TABLE 123 FRANCE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 176
10.3.5 SPAIN 176
10.3.5.1 Rising incidence of chronic diseases to support market growth 176
TABLE 124 SPAIN: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 177
TABLE 125 SPAIN: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 177
TABLE 126 SPAIN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 177
TABLE 127 SPAIN: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 128 SPAIN: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 129 SPAIN: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 179
TABLE 130 SPAIN: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 179
TABLE 131 SPAIN: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 179
TABLE 132 SPAIN: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 180
10.3.6 ITALY 180
10.3.6.1 Increasing focus on preventive care to support market growth 180
TABLE 133 ITALY: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 180
TABLE 134 ITALY: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 181
TABLE 135 ITALY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 181
TABLE 136 ITALY: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 182
TABLE 137 ITALY: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 182
TABLE 138 ITALY: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 183
TABLE 139 ITALY: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 183
TABLE 140 ITALY: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 183
TABLE 141 ITALY: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 184
10.3.7 REST OF EUROPE 184
TABLE 142 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 185
TABLE 143 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 185
TABLE 144 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 185
TABLE 145 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 186
TABLE 146 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 186
TABLE 147 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 148 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 187
TABLE 149 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 187
TABLE 150 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 188
10.4 ASIA PACIFIC 188
TABLE 151 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 188
TABLE 152 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 189
TABLE 153 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 189
TABLE 154 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 189
TABLE 155 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 190
TABLE 156 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 190
TABLE 157 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 158 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 191
TABLE 159 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 191
TABLE 160 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 192
10.4.1 ASIA PACIFIC: RECESSION IMPACT 192
10.4.2 JAPAN 193
10.4.2.1 Rising incidence of diabetes to propel market 193
TABLE 161 JAPAN: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 193
TABLE 162 JAPAN: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 193
TABLE 163 JAPAN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 194
TABLE 164 JAPAN: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 194
TABLE 165 JAPAN: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 195
TABLE 166 JAPAN: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 195
TABLE 167 JAPAN: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 195
TABLE 168 JAPAN: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 196
TABLE 169 JAPAN: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 196
10.4.3 CHINA 196
10.4.3.1 Rising investments in application development to propel market 196
TABLE 170 CHINA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 197
TABLE 171 CHINA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 197
TABLE 172 CHINA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 197
TABLE 173 CHINA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 174 CHINA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 175 CHINA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 199
TABLE 176 CHINA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 199
TABLE 177 CHINA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 199
TABLE 178 CHINA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 200
10.4.4 INDIA 200
10.4.4.1 Low patient adherence to prescribed treatments to support market growth 200
TABLE 179 INDIA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 200
TABLE 180 INDIA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 201
TABLE 181 INDIA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 201
TABLE 182 INDIA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 183 INDIA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 184 INDIA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 203
TABLE 185 INDIA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 203
TABLE 186 INDIA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 203
TABLE 187 INDIA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 204
10.4.5 REST OF ASIA PACIFIC 204
TABLE 188 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 204
TABLE 189 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 205
TABLE 190 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 205
TABLE 191 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 206
TABLE 192 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 206
TABLE 193 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 207
TABLE 194 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 207
TABLE 195 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 207
TABLE 196 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 208

10.5 LATIN AMERICA 208
TABLE 197 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 208
TABLE 198 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 209
TABLE 199 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 209
TABLE 200 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 210
TABLE 201 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 210
TABLE 202 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 203 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 211
TABLE 204 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 211
TABLE 205 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 212
10.5.1 LATIN AMERICA: RECESSION IMPACT 212
10.5.2 BRAZIL 212
10.5.2.1 Growing acceptance of evidence-based software applications to boost demand 212
TABLE 206 BRAZIL: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 213
TABLE 207 BRAZIL: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 213
TABLE 208 BRAZIL: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 213
TABLE 209 BRAZIL: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 214
TABLE 210 BRAZIL: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 214
TABLE 211 BRAZIL: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 215
TABLE 212 BRAZIL: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 215
TABLE 213 BRAZIL: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 215
TABLE 214 BRAZIL: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 216
10.5.3 MEXICO 216
10.5.3.1 Growth in target patient population to support market growth 216
TABLE 215 MEXICO: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 216
TABLE 216 MEXICO: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 217
TABLE 217 MEXICO: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 217
TABLE 218 MEXICO: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 218
TABLE 219 MEXICO: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 218
TABLE 220 MEXICO: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 219
TABLE 221 MEXICO: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 219
TABLE 222 MEXICO: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 219
TABLE 223 MEXICO: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 220
10.5.4 REST OF LATIN AMERICA 220
TABLE 224 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 220
TABLE 225 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 221
TABLE 226 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 221
TABLE 227 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 222
TABLE 228 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 222
TABLE 229 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 223
TABLE 230 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 223
TABLE 231 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 223
TABLE 232 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 224
10.6 MIDDLE EAST & AFRICA 224
TABLE 233 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 224
TABLE 234 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 225
TABLE 235 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 225
TABLE 236 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 226
TABLE 237 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 226
TABLE 238 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 227
TABLE 239 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 227
TABLE 240 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 227
TABLE 241 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 228
10.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT 228
10.6.2 GCC COUNTRIES 228
10.6.2.1 Improvements in healthcare infrastructure to drive market 228
TABLE 242 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 229
TABLE 243 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 229
TABLE 244 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 229
TABLE 245 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 230
TABLE 246 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 230
TABLE 247 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 231
TABLE 248 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 231
TABLE 249 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 231
TABLE 250 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 232
10.6.3 REST OF MIDDLE EAST & AFRICA 232
TABLE 251 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 232
TABLE 252 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION) 233
TABLE 253 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 233
TABLE 254 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 234
TABLE 255 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 234
TABLE 256 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION) 235
TABLE 257 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 235
TABLE 258 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 235
TABLE 259 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 236
11 COMPETITIVE LANDSCAPE 237
11.1 OVERVIEW 237
11.2 KEY PLAYER STRATEGIES 237
FIGURE 33 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 238
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 238
11.3.1 REVENUE ANALYSIS OF KEY PLAYERS IN DIGITAL THERAPEUTICS MARKET, 2020–2022 (USD MILLION) 239
11.4 MARKET SHARE ANALYSIS 239
TABLE 260 DIGITAL THERAPEUTICS MARKET: INTENSITY OF COMPETITIVE RIVALRY 239
FIGURE 34 DIGITAL THERAPEUTICS MARKET: MARKET SHARE ANALYSIS 240
11.5 COMPANY EVALUATION MATRIX 241
11.5.1 STARS 241
11.5.2 EMERGING LEADERS 241
11.5.3 PERVASIVE PLAYERS 241
11.5.4 PARTICIPANTS 241
FIGURE 35 DIGITAL THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX (2022) 242
11.5.5 COMPANY FOOTPRINT 242
TABLE 261 DIGITAL THERAPEUTICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 242
TABLE 262 DIGITAL THERAPEUTICS MARKET: OFFERING FOOTPRINT ANALYSIS, BY KEY PLAYER 244
TABLE 263 DIGITAL THERAPEUTICS MARKET: APPLICATION FOOTPRINT ANALYSIS, BY KEY PLAYER 245
TABLE 264 DIGITAL THERAPEUTICS MARKET: SALES CHANNEL FOOTPRINT ANALYSIS, BY KEY PLAYER 246
TABLE 265 DIGITAL THERAPEUTICS MARKET: REGIONAL FOOTPRINT ANALYSIS, BY KEY PLAYER 247
11.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES 248
11.6.1 PROGRESSIVE COMPANIES 248
11.6.2 RESPONSIVE COMPANIES 248
11.6.3 DYNAMIC COMPANIES 248
11.6.4 STARTING BLOCKS 249
FIGURE 36 DIGITAL THERAPEUTICS MARKET: STARTUP/SME EVALUATION MATRIX (2022) 249
11.6.5 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 250
TABLE 266 DETAILED LIST OF KEY STARTUPS/SMES 250
TABLE 267 COMPETITIVE BENCHMARKING OF STARTUPS/SMES, BY REGION 251
11.7 COMPETITIVE SCENARIOS AND TRENDS 251
TABLE 268 DIGITAL THERAPEUTICS MARKET: PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS (JANUARY 2020–NOVEMBER 2023) 251
11.7.1 DEALS 254
TABLE 269 DIGITAL THERAPEUTICS MARKET: DEALS (JANUARY 2020–NOVEMBER 2023) 254
11.7.2 OTHER DEVELOPMENTS 258
TABLE 270 DIGITAL THERAPEUTICS MARKET: OTHER DEVELOPMENTS (JANUARY 2020–NOVEMBER 2023) 258
12 COMPANY PROFILES 260
12.1 KEY PLAYERS 260
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
12.1.1 NOOM, INC. 260
TABLE 271 NOOM, INC.: BUSINESS OVERVIEW 260
12.1.2 TELADOC HEALTH, INC. 263
TABLE 272 TELADOC HEALTH, INC.: BUSINESS OVERVIEW 263
FIGURE 37 TELADOC HEALTH, INC.: COMPANY SNAPSHOT (2022) 263
12.1.3 OMADA HEALTH, INC. 266
TABLE 273 OMADA HEALTH, INC.: BUSINESS OVERVIEW 266
12.1.4 WELLDOC, INC. 269
TABLE 274 WELLDOC, INC.: BUSINESS OVERVIEW 269
12.1.5 COGNIFIT, INC. 271
TABLE 275 COGNIFIT, INC.: BUSINESS OVERVIEW 271
12.1.6 HEADSPACE HEALTH 273
TABLE 276 HEADSPACE HEALTH: BUSINESS OVERVIEW 273
12.1.7 PROPELLER HEALTH 275
TABLE 277 PROPELLER HEALTH: BUSINESS OVERVIEW 275
12.1.8 2MORROW, INC. 277
TABLE 278 2MORROW, INC.: BUSINESS OVERVIEW 277
12.1.9 CANARY HEALTH 279
TABLE 279 CANARY HEALTH: BUSINESS OVERVIEW 279
12.1.10 CLICK THERAPEUTICS, INC. 281
TABLE 280 CLICK THERAPEUTICS: BUSINESS OVERVIEW 281
12.1.11 AKILI, INC. 283
TABLE 281 AKILI, INC.: BUSINESS OVERVIEW 283
12.1.12 WELLTHY THERAPEUTICS PVT. LTD. 285
TABLE 282 WELLTHY THERAPEUTICS PVT. LTD.: BUSINESS OVERVIEW 285
12.1.13 COGNOA, INC. 287
TABLE 283 COGNOA, INC.: BUSINESS OVERVIEW 287
12.1.14 TWILL INC. 289
TABLE 284 TWILL INC.: BUSINESS OVERVIEW 289
12.1.15 KAIA HEALTH SOFTWARE GMBH 290
TABLE 285 KAIA HEALTH SOFTWARE GMBH: BUSINESS OVERVIEW 290
12.1.16 BETTER THERAPEUTICS, INC. 292
TABLE 286 BETTER THERAPEUTICS, INC.: BUSINESS OVERVIEW 292
12.1.17 REALIZEDCARE 294
TABLE 287 REALIZEDCARE: BUSINESS OVERVIEW 294
12.1.18 BIOFOURMIS 295
TABLE 288 BIOFOURMIS: BUSINESS OVERVIEW 295
12.1.19 AYOGO INCORPORATED 296
TABLE 289 AYOGO INCORPORATED: BUSINESS OVERVIEW 296
12.1.20 AMALGAM RX, INC. 298
TABLE 290 AMALGAM RX, INC.: BUSINESS OVERVIEW 298
12.2 OTHER PLAYERS 299
12.2.1 MINDABLE HEALTH GMBH 299
12.2.2 VIRTA HEALTH CORP. 299
12.2.3 HINGE HEALTH 300
12.2.4 OREXO AB 300
12.2.5 FREESPIRA, INC. 301
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
13 APPENDIX 302
13.1 DISCUSSION GUIDE 302
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 306
13.3 CUSTOMIZATION OPTIONS 308
13.4 RELATED REPORTS 308
13.5 AUTHOR DETAILS 309

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 放射線量管理の世界市場予測（～2028）：提供別、モダリティ別、収益モデル別、用途別、エンドユーザー別
  • 遠隔患者モニタリング（RPM）の世界市場予測（～2028）：製品別、エンドユーザー別、地域別
  • 抗体薬物複合体（ADC）の世界市場予測（～2028）：製品別、リンカー種類別、ペイロード種類別、ターゲット別、疾患別、地域別
  • 着床前遺伝学的検査（PGT）の世界市場予測（～2028）：処置別、技術別、製品別、用途別、サイクル種類別、エンドユーザー別、地域別
  • テレヘルス・テレメディスン（遠隔医療）の世界市場予測（～2028）：コンポーネント別、デリバリー別、用途別、エンドユーザー別、地域別
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(HIT4407-24 )"デジタルセラピューティクス（DTx）の世界市場予測（～2028）：提供別、収益モデル別、用途別" (英文：Digital Therapeutics (DTx) Market by Offerings (Platform, Virtual Reality/Games), Revenue Model (Subscription, Value Based), Application (Therapy (Diabetes, Obesity, CNS, Respiratory, CVD), Drug Adherence, Rehab/Patient care) - Global Forecast to 2028)はMarketsandMarkets社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。